Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: CALGB 90802 Principal Investigator: Picus, Joel
Title: Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors
Phase: III Disease Site: Kidney
Participating Site(s):
 
Main Campus
Map and Directions
South County
Map and Directions
St. Peters
Map and Directions
West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to compare the effects of a drug called everolimus alone with those of the combination of everolimus and a drug called bevacizumab for advanced kidney cancer to find out which is better. In this study, patients will get either the combination of everolimus and a placebo or the combination of everolimus and bevacizumab.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)